Literature DB >> 2140788

Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.

C A Waters1, P A Schimke, C E Snider, K Itoh, K A Smith, J C Nichols, T B Strom, J R Murphy.   

Abstract

The receptor binding requirements for entry of the NAD+ ADP-ribosyltransferase component of DAB486-IL 2 into target cells were examined. Experiments utilizing cell lines bearing either high-affinity or individual subunits of the interleukin 2 receptor (IL 2R) as well as human peripheral blood mononuclear cells with natural killer activity demonstrate that the high-affinity receptor facilitates delivery of fragment A from DAB486-IL 2 to the cytosol approximately 1000 times more efficiently than either the intermediate-(p75) or low-affinity (p55) forms of the IL 2R. We show that elongation factor 2 (EF-2) in these cells is not quantitatively or qualitatively altered indicating that the relative resistance to intoxication displayed by IL 2R variant cell lines cannot be attributed to an altered intracellular target of the hybrid toxin. We also demonstrate that an alteration in the binding of DAB486-IL 2 to the p75 subunit of the IL 2R may account for the selective cytotoxicity of DAB486-IL 2 for cells bearing the heterodimeric high-affinity IL 2R.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140788     DOI: 10.1002/eji.1830200412

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.

Authors:  P Bacha; S Forte; N Kassam; J Thomas; D Akiyoshi; C Waters; J Nichols; M Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice.

Authors:  Mahendra K Bhopale; Brendan Hilliard; Cris S Constantinescu; S Michael Phillips; Abdolmohamad Rostami
Journal:  Immunopharmacol Immunotoxicol       Date:  2017-09-20       Impact factor: 2.730

4.  Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.

Authors:  A Bousvaros; A C Stevens; T B Strom; J Murphy; J T Lamont
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

Authors:  Daniel J Powell; Aloisio Felipe-Silva; Maria J Merino; Mojgan Ahmadzadeh; Tamika Allen; Catherine Levy; Donald E White; Sharon Mavroukakis; Robert J Kreitman; Steven A Rosenberg; Ira Pastan
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

6.  Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Authors:  Peter Attia; Daniel J Powell; Ajay V Maker; Robert J Kreitman; Ira Pastan; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

7.  Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.

Authors:  J vanderSpek; L Cosenza; T Woodworth; J C Nichols; J R Murphy
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

8.  Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor.

Authors:  J G Pickering; P A Bacha; L Weir; J Jekanowski; J C Nichols; J M Isner
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

9.  Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.

Authors:  Daniel J Powell; Peter Attia; Victor Ghetie; John Schindler; Ellen S Vitetta; Steven A Rosenberg
Journal:  J Immunother       Date:  2008 Feb-Mar       Impact factor: 4.456

10.  Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

Authors:  Michael A Morse; Amy C Hobeika; Takuya Osada; Delila Serra; Donna Niedzwiecki; H Kim Lyerly; Timothy M Clay
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.